Stassar M J, Devitt G, Brosius M, Rinnab L, Prang J, Schradin T, Simon J, Petersen S, Kopp-Schneider A, Zöller M
Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg, 69120.
Br J Cancer. 2001 Nov 2;85(9):1372-82. doi: 10.1054/bjoc.2001.2074.
Renal cell carcinoma (RCC) are frequently chemo- and radiation resistant. Thus, there is a need for identifying biological features of these cells that could serve as alternative therapeutic targets. We performed suppression subtractive hybridization (SSH) on patient-matched normal renal and RCC tissue to identify variably regulated genes. 11 genes were strongly up-regulated or selectively expressed in more than one RCC tissue or cell line. Screening of filters containing cancer-related cDNAs confirmed overexpression of 3 of these genes and 3 additional genes were identified. These 14 differentially expressed genes, only 6 of which have previously been associated with RCC, are related to tumour growth/survival (EGFR, cyclin D1, insulin-like growth factor-binding protein-1 and a MLRQ sub-unit homologue of the NADH:ubiquinone oxidoreductase complex), angiogenesis (vascular endothelial growth factor, endothelial PAS domain protein-1, ceruloplasmin, angiopoietin-related protein 2) and cell adhesion/motility (protocadherin 2, cadherin 6, autotaxin, vimentin, lysyl oxidase and semaphorin G). Since some of these genes were overexpressed in 80-90% of RCC tissues, it is important to evaluate their suitability as therapeutic targets.
肾细胞癌(RCC)通常对化疗和放疗具有抗性。因此,需要确定这些细胞的生物学特征,以便将其作为替代治疗靶点。我们对患者匹配的正常肾组织和肾细胞癌组织进行了抑制性消减杂交(SSH),以鉴定差异表达的基因。11个基因在不止一个肾细胞癌组织或细胞系中强烈上调或选择性表达。对含有癌症相关cDNA的滤膜进行筛选,证实其中3个基因过表达,并鉴定出另外3个基因。这14个差异表达基因中,只有6个先前与肾细胞癌相关,它们与肿瘤生长/存活(表皮生长因子受体、细胞周期蛋白D1、胰岛素样生长因子结合蛋白-1以及NADH:泛醌氧化还原酶复合物的一个MLRQ亚基同系物)、血管生成(血管内皮生长因子、内皮PAS结构域蛋白-1、铜蓝蛋白、血管生成素相关蛋白2)以及细胞黏附/运动(原钙黏蛋白2、钙黏蛋白6、自分泌运动因子、波形蛋白、赖氨酰氧化酶和信号素G)有关。由于其中一些基因在80%-90%的肾细胞癌组织中过表达,因此评估它们作为治疗靶点的适用性非常重要。